T. Rowe Price Associates’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

T. Rowe Price Associates’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-617	Closed	-$94K	–	2733
2020 Q3	$94K	Buy	+617	New	+$101K	﹤0.01%	2514
2017 Q2	–	Sell	-67	Closed	-$22K	–	2584
2017 Q1	$22K	Hold	67	–	–	﹤0.01%	2561
2016 Q4	$40K	Hold	67	–	–	﹤0.01%	2536
2016 Q3	$76K	Hold	67	–	–	﹤0.01%	2472
2016 Q2	$73K	Hold	67	–	–	﹤0.01%	2461
2016 Q1	$86K	Hold	67	–	–	﹤0.01%	2427
2015 Q4	$164K	Buy	67 +38	+131%	+$58.3K	﹤0.01%	2343
2015 Q3	$32K	Hold	29	–	–	﹤0.01%	2490
2015 Q2	$29K	Hold	29	–	–	﹤0.01%	2520
2015 Q1	$30K	Sell	29 -4	-12%	-$13.2K	﹤0.01%	2526
2014 Q4	$108K	Sell	33 -3	-8%	-$9.2K	﹤0.01%	2463
2014 Q3	$103K	Hold	36	–	–	﹤0.01%	2469
2014 Q2	$135K	Buy	36 +8	+29%	+$30.1K	﹤0.01%	2435
2014 Q1	$152K	Hold	28	–	–	﹤0.01%	2376
2013 Q4	$88K	Buy	+28	New	+$86.3K	﹤0.01%	2417

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.02% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FWM

Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

T. Rowe Price Associates's NBSE Position: Q4 2020 in Review

T. Rowe Price Associates sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2020, closing a stake of 617 shares — an estimated $94K sold.

T. Rowe Price Associates first reported a position in NBSE in Q4 2013 and held it in 15 quarters. The position peaked at $164K in Q4 2015. 53 funds tracked by Wall St. Rank hold NBSE as of Q4 2020.

T. Rowe Price Associates reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
T. Rowe Price Associates sold 617 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $94K.
T. Rowe Price Associates first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2013 and held it in 15 quarters.
T. Rowe Price Associates's NeuBase Therapeutics, Inc. Common Stock position peaked at $164K in Q4 2015.
53 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2020.

Based on T. Rowe Price Associates's 13F filing for Q4 2020, filed 16 Feb 2021.